Answers are grounded in this paper and cite their sources.
Assesses cytotoxicity in nanomaterials, suggesting improved analysis efficiency without labeling.
With the rise of nanomaterials in biomedical applications, the need for accurate and non‐invasive cytotoxicity characterization is clear. Current methods assessing nanomaterial cytotoxicity are indirect, well‐plate‐based fluorescence assays, or complex microscopy techniques. Herein, we present FluoAI, a two‐stage neural network‐based live/dead cell classifier for quantifying cytotoxicity without the need for external labeling. The workflow uses two convolutional neural networks. First, Mask R‐CNN instance segments grayscale fluorescence microscopy images isolating individual cells. In the second stage, segmented cells are analyzed by a DenseNet‐121 classifier that assigns live/dead labels, reaching performance accuracy of up to 92.0%. In addition to its live/dead cell classification, FluoAI performs expert‐level analyses, including corrected total cell fluorescence, mean fluorescence, and cell area, with comparisons showing minimal to no significant differences from human expert measurements. Since the pipeline is fully automated, FluoAI can produce quantitative fluorescence assessments significantly faster than a human expert while retaining similar accuracy. This method provides a practical fluorescence microscopy‐based workflow for cytotoxicity assessment without an additional live/dead staining step and enables automated in vitro analysis of routine fluorescence microscopy data. With expanding datasets, FluoAI may support more reliable and higher‐throughput nano‐cytotoxicity analysis and automated assessment of fluorescent nanomaterials, accelerating the development of safer nanomedicine.
No takes yet. Share an insight, caveat, or question.
Topkiran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: